Sana Biotechnology Files Q1 2025 10-Q
Ticker: SANA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1770121
Sentiment: neutral
Topics: 10-Q, biotechnology, financials, SEC filing
TL;DR
Sana Bio's Q1 2025 10-Q is in. Check financials, stock, and warrants.
AI Summary
Sana Biotechnology, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations, including references to various agreements and financial instruments such as common stock, pre-funded warrants, and employee stock options. The company's principal executive offices are located at 188 East Blaine Street, Suite 400, Seattle, WA.
Why It Matters
This filing provides investors with an update on Sana Biotechnology's financial health and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — Biotechnology companies often carry higher risk due to the nature of research and development, regulatory hurdles, and market volatility.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the financial period covered by the report.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Sana Biotechnology, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- 188 East Blaine Street, Suite 400, Seattle, WA 98102 (address) — Company business and mailing address
- Beam Therapeutics Incorporated (company) — Mentioned in relation to a date
- Cobalt Biomedicine Inc (company) — Mentioned in relation to an acquisition agreement
FAQ
What is the primary business of Sana Biotechnology, Inc.?
Sana Biotechnology, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
What is the fiscal year end for Sana Biotechnology, Inc.?
The fiscal year end for Sana Biotechnology, Inc. is December 31 (1231).
When was the acquisition agreement with Cobalt Biomedicine Inc. mentioned?
The acquisition agreement with Cobalt Biomedicine Inc. is mentioned in relation to the date 2019-02-28.
What financial instruments are specifically mentioned for the period of January 1, 2025, to March 31, 2025?
For the period of January 1, 2025, to March 31, 2025, the filing mentions 'OfficeAndLaboratoryMember', 'EmployeeStockOptionMember', and 'LongTermFinancialLiabilities'.
What is the SEC file number for Sana Biotechnology, Inc.?
The SEC file number for Sana Biotechnology, Inc. is 001-39941.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Sana Biotechnology, Inc. (SANA).